Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Literature DB >> 23455378

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Kenta Masui¹, Beatrice Gini, Jill Wykosky, Ciro Zanca, Paul S Mischel, Frank B Furnari, Webster K Cavenee.

Abstract

Chemotherapy and molecularly targeted approaches represent two very different modes of cancer treatment and each is associated with unique benefits and limitations. Both types of therapy share the overarching limitation of the emergence of drug resistance, which prevents these drugs from eliciting lasting clinical benefit. This review will provide an overview of the various mechanisms of resistance to each of these classes of drugs and examples of drug combinations that have been tested clinically. This analysis supports the contention that understanding modes of resistance to both chemotherapy and molecularly targeted therapies may be very useful in selecting those drugs of each class that will have complementing mechanisms of sensitivity and thereby represent reasonable combination therapies.

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2013 PMID： 23455378 PMCID： PMC3616676 DOI： 10.1093/carcin/bgt086

Source DB: PubMed Journal: Carcinogenesis ISSN： 0143-3334 Impact factor: 4.944

203 in total

Review 1. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors: Magnus Ingelman-Sundberg
Journal: Trends Pharmacol Sci Date: 2004-04 Impact factor: 14.819

2. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Authors: Tadaaki Yamada; Shinji Takeuchi; Junya Nakade; Kenji Kita; Takayuki Nakagawa; Shigeki Nanjo; Takahiro Nakamura; Kunio Matsumoto; Manabu Soda; Hiroyuki Mano; Toshimitsu Uenaka; Seiji Yano
Journal: Clin Cancer Res Date: 2012-05-02 Impact factor: 12.531

Review 3. Liposomal drug formulations in cancer therapy: 15 years along the road.

Authors: Marije Slingerland; Henk-Jan Guchelaar; Hans Gelderblom
Journal: Drug Discov Today Date: 2011-09-29 Impact factor: 7.851

4. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245

5. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors: Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal: Clin Cancer Res Date: 2006-11-01 Impact factor: 12.531

6. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

Authors: Ozgur Kutuk; Anthony Letai
Journal: Cancer Res Date: 2008-10-01 Impact factor: 12.701

7. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544

Review 8. Targeting multidrug resistance in cancer.

Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694

9. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316

10. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors: Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal: Nature Date: 2009-12-24 Impact factor: 49.962

31 in total

1. Low-dose chemotherapeutic drugs induce reactive oxygen species and initiate apoptosis-mediated genomic instability.

Authors: Renganathan Arun; Sridaran Dhivya; Suresh K Abraham; Kumpati Premkumar
Journal: Toxicol Res (Camb) Date: 2016-01-07 Impact factor: 3.524

2. The promise of single-cell mechanophenotyping for clinical applications.

Authors: Molly Kozminsky; Lydia L Sohn
Journal: Biomicrofluidics Date: 2020-06-09 Impact factor: 2.800

Review 3. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors: Mariusz Panczyk
Journal: World J Gastroenterol Date: 2014-08-07 Impact factor: 5.742

4. KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.

Authors: Xiaoni Liu; Shang-Min Zhang; Marcus W Bosenberg; Qin Yan; Meaghan K McGeary; Irina Krykbaeva; Ling Lai; Daniel J Jansen; Stephen C Kales; Anton Simeonov; Matthew D Hall; Daniel P Kelly
Journal: Mol Cancer Ther Date: 2018-12-06 Impact factor: 6.261

5. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.

Authors: Wentong Fang; Chengheng Liao; Rachel Shi; Jeremy M Simon; Travis S Ptacek; Giada Zurlo; Youqiong Ye; Leng Han; Cheng Fan; Lei Bao; Christopher Llynard Ortiz; Hong-Rui Lin; Ujjawal Manocha; Weibo Luo; Yan Peng; William Y Kim; Lee-Wei Yang; Qing Zhang
Journal: Elife Date: 2021-11-15 Impact factor: 8.140

6. Falcarindiol and dichloromethane fraction are bioactive components in Oplopanax elatus: Colorectal cancer chemoprevention via induction of apoptosis and G2/M cell cycle arrest mediated by cyclin A upregulation.

Authors: Chong-Zhi Wang; Yun Luo; Wei-Hua Huang; Jinxiang Zeng; Chun-Feng Zhang; Mallory Lager; Wei Du; Ming Xu; Chun-Su Yuan
Journal: J Appl Biomed Date: 2021 Impact factor: 1.797

7. mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM.

Authors: Praveen Bhoopathi; Nathaniel Lee; Anjan K Pradhan; Xue-Ning Shen; Swadesh K Das; Devanand Sarkar; Luni Emdad; Paul B Fisher
Journal: Cancer Res Date: 2016-04-13 Impact factor: 12.701

8. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.

Authors: Ashley R Rowson-Hodel; Anastasia L Berg; Jessica H Wald; Jason Hatakeyama; Kacey VanderVorst; Daniel A Curiel; Leonardo J Leon; Colleen Sweeney; Kermit L Carraway
Journal: Cancer Lett Date: 2016-03-02 Impact factor: 8.679

9. Cancer cell-selective killing polymer/copper combination.

Authors: Huacheng He; Diego Altomare; Ufuk Ozer; Hanwen Xu; Kim Creek; Hexin Chen; Peisheng Xu
Journal: Biomater Sci Date: 2016-01 Impact factor: 6.843

10. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.

Authors: Ying C Henderson; Abdallah S R Mohamed; Anastasios Maniakas; Yunyun Chen; Reid T Powell; Shaohua Peng; Maria Cardenas; Michelle D Williams; Diana Bell; Mark E Zafereo; Rui Jennifer Wang; Steve E Scherer; David A Wheeler; Maria E Cabanillas; Marie-Claude Hofmann; Faye M Johnson; Clifford C Stephan; Vlad Sandulache; Stephen Y Lai
Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134